Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 4 months ago

Possible Interaction: Amphetamine and Naloxone

supplement:

Amphetamine

Research Papers that Mention the Interaction

The finding that an enantiomer of naloxone , with no opiate antagonist activity, is able to block the excitatory action of amphetamine , suggests the existence of a hitherto unknown mechanism of counteracting some of the effects of stimulants and euphoriants like amphetamine and cocaine.
When treated simultaneously with amphetamine and l-naloxone , these subjects showed low motility.
Pharmacology Biochemistry and Behavior  •  1998  |  View Paper
However, the exact nature of the NX induced alteration of AMPH induced behaviors is controversial, with some studies using high (5-40 mg/kg) doses of NX reporting an inhibition, and others using low (< or = 1-2 mg/kg) doses observing a potentiation.
NX pretreatment (0.8 mg/kg) … by a higher dose of AMPH (3.0 mg/kg) produced a significantly greater cumulative effect on DA release than saline pretreatment over the last … combined intervals (30-90 min) and over two grouped intervals (30-50 min and 40-60 min inclusive).
On the other hand, the same dose of NX significantly enhanced AMPH induced striatal DA release relative to saline pretreated animals during each of four separate intervals, from 30 to 70 minutes following AMPH (1.5 mg/kg), and across all nine intervals combined.
The opiate antagonist naloxone (NX) alters amphetamine (AMPH) induced behaviors including locomotor activity, rearing and stereotypy.
The present results suggest that NX potentiates AMPH induced striatal DA release when lower doses of NX are used.
These results combined with those of previous studies also suggest that NX exerts a biphasic effect on AMPH induced DA release, with lower doses potentiating release and higher doses inhibiting release.
Life sciences  •  1997  |  View Paper
The specific opioid receptor antagonist naloxone attenuates the behavioral and neurochemical effects of amphetamine.
Journal of neurochemistry  •  1996  |  View Paper
Naloxone pretreatment significantly reduced the amphetamine-induced increase in extracellular dopamine in both brain regions and also attenuated the increase in locomotor activity elicited by amphetamine.
The specific opioid receptor antagonist naloxone modifies the effects of amphetamine in a wide variety of behavioral paradigms.
European journal of pharmacology  •  1995  |  View Paper
Naloxone and naltrindole attenuate the locomotor response to amphetamine , implicating delta-opioid receptors in the opioid-antagonist/amphetamine interaction.
European journal of pharmacology  •  1993  |  View Paper
Gross locomotor counts following AMPH administration were significantly lower for rats pretreated with NX than for rats pretreated with saline.
However, compared to pretreatment with saline pretreatment with NX significantly decreased the dopaminergic response to AMPH in the STR.
These findings suggest that a decrease in the dopaminergic response to AMPH is the mechanism by which NX attenuates behavioral stimulant effects of AMPH.
This study tested the possibility that naloxone (NX), an opioid antagonist, reduces the behavioral effects of amphetamine (AMPH) in rats by attenuating the dopaminergic response to AMPH.
Pharmacology Biochemistry and Behavior  •  1992  |  View Paper
In contrast, amphetamine , a DA-releasing agent, significantly increased DA release in the presence of naloxone.
Neuroendocrinology  •  1991  |  View Paper
Naloxone , at all three doses examined, prevented the ability of amphetamine to produce a place preference.
Thus, the lowest dose of naloxone , having no effects alone in place conditioning was still able to block the reinforcing effects of amphetamine.
Psychopharmacology  •  1991  |  View Paper
Locomotor activation produced by the indirect dopamine (DA) agonist amphetamine is reversed by the opiate-receptor antagonist naloxone.
Naloxone (0-2 mg/kg) had no significant effect of DA-stimulated locomotion; the lowest dose of naloxone tested (0.5 mg/kg) was shown to significantly disrupt the locomotor activation produced by amphetamine (0.5 mg/kg).
Pharmacology Biochemistry and Behavior  •  1987  |  View Paper
The combined administration of naloxone with amphetamine had an additive suppressive effect on responding.
Pharmacology Biochemistry and Behavior  •  1987  |  View Paper
Show More